Abraxane

The clearance of Cipla's Goa facility opens the doors for the launch of Abraxane, which could be a around $120 million opportunity at peak.

Cipla: M&A positioning, new US regime are key wild cards

The management is primarily focusing on Indian assets which can bring synergy, followed by US assets. Cipla’s continued investment in US subsidiary InvaGen would de-risk the business model from a compliance point of view.

Cipla: Watch out for respiratory and Peptide pipelines

Cipla is building its Peptide pipeline with the recently launched Lanreotide injection, which has been well received

Biosimilars to lead growth; generics to be a small part: Biocon

Biotechnology major Biocon reported 19.8 percent rise in revenue to Rs 796.2 crore year-on-year and margins grew to 25.2 percent from 21.2 percent in the second quarter of FY17. The company‘s standalones sale grew 17 percent in Q2.

Celgene announces USFDA grants Priority Review for ABRAXANE

Celgene International Sàrl announced that the US Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.